Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bradley Kessler

Pediatric Gastroenterology West Islip, NY Medical Doctor

NPI 1700887551 CMS profile 259091

1000 Montauk Hwy, West Islip, NY 11795

Open in the dashboard

General payments

$5,588

199 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bradley Kessler of West Islip, NY is reported in the CMS Open Payments database as having received $5,588 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,838 50
2024 General $847 41
2023 General $1,384 51
2022 General $519 23
2021 General $424 17
2020 General $182 9
2019 General $393 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradley Kessler
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Bradley Kessler were reported at $1,838. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Bradley Kessler Pediatric Gastroenterology median Middle half National median
2019 $393 $131 $41–$311 $163
2020 $182 $79 $23–$223 $114
2021 $424 $104 $32–$321 $132
2022 $519 $125 $37–$331 $149
2023 $1,384 $169 $55–$440 $160
2024 $847 $196 $73–$563 $164
2025 $1,838 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,574 41 payments
  2. Genzyme Corporation $821 28 payments
  3. Mirum Pharmaceuticals, Inc. $448 5 payments
  4. Supernus Pharmaceuticals, Inc. $250 14 payments
  5. Corium, Inc. $172 13 payments
  6. Janssen Biotech, Inc. $169 3 payments
  7. Regeneron Healthcare Solutions, Inc. $167 3 payments
  8. Pfizer Inc. $159 4 payments
  9. Xeris Pharmaceuticals, Inc. $147 7 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $143 8 payments
  11. Other $1,538 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,588 199 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $868 30 payments
  2. HUMIRA $461 16 payments
  3. Livmarli $430 4 payments
  4. RINVOQ $417 14 payments
  5. SKYRIZI Immunology $296 9 payments
  6. LUPRON DEPOT $192 7 payments
  7. Azstarys $172 13 payments
  8. TREMFYA $169 3 payments
  9. DUPIXENT Inflammation And Immunology $167 3 payments
  10. SKYRIZI Immunology $166 7 payments
  11. Other $2,203 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record